{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:45:28Z","timestamp":1790721928352,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T00:00:00Z","timestamp":1517875200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s11239-018-1619-0","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T10:26:34Z","timestamp":1517912794000},"page":"457-462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A rare CALR variant mutation and a review of CALR in essential thrombocythemia"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4058-4616","authenticated-orcid":false,"given":"Robert","family":"Diep","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ara","family":"Metjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,6]]},"reference":[{"issue":"12","key":"1619_CR1","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s00432-015-1983-5","volume":"141","author":"MA Deadmond","year":"2015","unstructured":"Deadmond MA, Smith-Gagen JA (2015) Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973\u20132011. J Cancer Res Clin Oncol 141(12):2131\u20132138. \n                    https:\/\/doi.org\/10.1007\/s00432-015-1983-5","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"1619_CR2","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.mayocp.2015.05.014","volume":"90","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Barbui T (2015) Essential thrombocythemia and polycythemia vera: focus on clinical practice. Mayo Clin Proc 90(9):1283\u20131293. \n                    https:\/\/doi.org\/10.1016\/j.mayocp.2015.05.014","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"1619_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","volume":"128","author":"MA Elliott","year":"2005","unstructured":"Elliott MA, Tefferi A (2005) Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 128(3):275\u2013290. \n                    https:\/\/doi.org\/10.1111\/j.1365-2141.2004.05277.x","journal-title":"Br J Haematol"},{"issue":"4","key":"1619_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1600-0609.2006.00715.x","volume":"77","author":"N Gangat","year":"2006","unstructured":"Gangat N, Wolanskyj AP, Tefferi A (2006) Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications. Eur J Haematol 77(4):327\u2013333. \n                    https:\/\/doi.org\/10.1111\/j.1600-0609.2006.00715.x","journal-title":"Eur J Haematol"},{"issue":"25","key":"1619_CR5","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant\u2019Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schonegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379\u20132390. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1311347","journal-title":"N Engl J Med"},{"issue":"25","key":"1619_CR6","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O\u2019Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJ, Harrison CN, Cross NC, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391\u20132405. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1312542","journal-title":"N Engl J Med"},{"issue":"12","key":"1619_CR7","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s00277-014-2151-8","volume":"93","author":"CC Chen","year":"2014","unstructured":"Chen CC, Gau JP, Chou HJ, You JY, Huang CE, Chen YY, Lung J, Chou YS, Leu YW, Lu CH, Lee KD, Tsai YH (2014) Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia. Ann Hematol 93(12):2029\u20132036. \n                    https:\/\/doi.org\/10.1007\/s00277-014-2151-8","journal-title":"Ann Hematol"},{"issue":"10","key":"1619_CR8","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","volume":"123","author":"G Rotunno","year":"2014","unstructured":"Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, Fanelli T, Bosi A, Vannucchi AM, Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative I (2014) Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 123 (10):1552\u20131555. \n                    https:\/\/doi.org\/10.1182\/blood-2013-11-538983","journal-title":"Blood"},{"key":"1619_CR9","unstructured":"CALR calreticulin [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004 \u2013 [cited 2017\/05\/20]. \n                    https:\/\/www.ncbi.nlm.nih.gov\/gene\/811"},{"issue":"2","key":"1619_CR10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/leu.2015.277","volume":"30","author":"D Pietra","year":"2016","unstructured":"Pietra D, Rumi E, Ferretti VV, Di Buduo CA, Milanesi C, Cavalloni C, Sant\u2019Antonio E, Abbonante V, Moccia F, Casetti IC, Bellini M, Renna MC, Roncoroni E, Fugazza E, Astori C, Boveri E, Rosti V, Barosi G, Balduini A, Cazzola M (2016) Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 30(2):431\u2013438. \n                    https:\/\/doi.org\/10.1038\/leu.2015.277","journal-title":"Leukemia"},{"key":"1619_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3978\/j.issn.2306-9759.2015.08.01","volume":"2","author":"W Luo","year":"2015","unstructured":"Luo W, Yu Z (2015) Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs). Stem Cell Investig 2:16. \n                    https:\/\/doi.org\/10.3978\/j.issn.2306-9759.2015.08.01","journal-title":"Stem Cell Investig"},{"issue":"1","key":"1619_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3343\/alm.2015.35.1.22","volume":"35","author":"JS Ha","year":"2015","unstructured":"Ha JS, Kim YK (2015) Calreticulin exon 9 mutations in myeloproliferative neoplasms. Ann Lab Med 35(1):22\u201327. \n                    https:\/\/doi.org\/10.3343\/alm.2015.35.1.22","journal-title":"Ann Lab Med"},{"issue":"4","key":"1619_CR13","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/leu.2016.280","volume":"31","author":"K Kollmann","year":"2017","unstructured":"Kollmann K, Warsch W, Gonzalez-Arias C, Nice FL, Avezov E, Milburn J, Li J, Dimitropoulou D, Biddie S, Wang M, Poynton E, Colzani M, Tijssen MR, Anand S, McDermott U, Huntly B, Green T (2017) A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation. Leukemia 31(4):934\u2013944. \n                    https:\/\/doi.org\/10.1038\/leu.2016.280","journal-title":"Leukemia"},{"issue":"10","key":"1619_CR14","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1182\/blood-2014-12-618074","volume":"125","author":"WW Lau","year":"2015","unstructured":"Lau WW, Hannah R, Green AR, Gottgens B (2015) The JAK-STAT signaling pathway is differentially activated in CALR-positive compared with JAK2V617F-positive ET patients. Blood 125(10):1679\u20131681. \n                    https:\/\/doi.org\/10.1182\/blood-2014-12-618074","journal-title":"Blood"},{"issue":"8","key":"1619_CR15","doi-asserted-by":"publisher","first-page":"E121","DOI":"10.1002\/ajh.23743","volume":"89","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, Finke C, Ketterling RP, Hanson CA, Pardanani A, Wolanskyj AP, Maffioli M, Casalone R, Pacilli A, Vannucchi AM, Passamonti F (2014) Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 89(8):E121\u2013E124. \n                    https:\/\/doi.org\/10.1002\/ajh.23743","journal-title":"Am J Hematol"},{"issue":"7","key":"1619_CR16","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","volume":"124","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martinez-Trillos A, Casetti I, Colomer D, Pieri L, Pratcorona M, Rotunno G, Sant\u2019Antonio E, Bellini M, Cavalloni C, Mannarelli C, Milanesi C, Boveri E, Ferretti V, Astori C, Rosti V, Cervantes F, Barosi G, Vannucchi AM, Cazzola M, Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (2014) Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 124(7):1062\u20131069. \n                    https:\/\/doi.org\/10.1182\/blood-2014-05-578435","journal-title":"Blood"},{"key":"1619_CR17","doi-asserted-by":"publisher","first-page":"e337","DOI":"10.1038\/bcj.2015.64","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, Thiele J, Vannucchi AM, Tefferi A (2015) Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J 5:e337. \n                    https:\/\/doi.org\/10.1038\/bcj.2015.64","journal-title":"Blood Cancer J"},{"issue":"3","key":"1619_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nrclinonc.2014.16","volume":"11","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Pardanani A (2014) Genetics: CALR mutations and a new diagnostic algorithm for MPN. Nat Rev Clin Oncol 11(3):125\u2013126. \n                    https:\/\/doi.org\/10.1038\/nrclinonc.2014.16","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"1619_CR19","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1182\/blood-2014-08-596676","volume":"124","author":"G Finazzi","year":"2014","unstructured":"Finazzi G, Carobbio A, Guglielmelli P, Cavalloni C, Salmoiraghi S, Vannucchi AM, Cazzola M, Passamonti F, Rambaldi A, Barbui T (2014) Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood 124(16):2611\u20132612. \n                    https:\/\/doi.org\/10.1182\/blood-2014-08-596676","journal-title":"Blood"},{"issue":"2","key":"1619_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/ajh.23895","volume":"90","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Barbui T (2015) Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 90(2):162\u2013173. \n                    https:\/\/doi.org\/10.1002\/ajh.23895","journal-title":"Am J Hematol"},{"issue":"8","key":"1619_CR21","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1038\/bcj.2016.75","volume":"6","author":"A Angona","year":"2016","unstructured":"Angona A, Fernandez-Rodriguez C, Alvarez-Larran A, Camacho L, Longaron R, Torres E, Pairet S, Besses C, Bellosillo B (2016) Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing. Blood Cancer J 6(8):e463. \n                    https:\/\/doi.org\/10.1038\/bcj.2016.75","journal-title":"Blood Cancer J"},{"issue":"9","key":"1619_CR22","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1179\/1607845415Y.0000000009","volume":"20","author":"QM Yao","year":"2015","unstructured":"Yao QM, Zhou J, Gale RP, Li JL, Li LD, Li N, Chen SS, Ruan GR (2015) A rapid, highly accurate method for quantifying CALR mutant allele burden in persons with myeloproliferative neoplasms. Hematology 20(9):517\u2013522. \n                    https:\/\/doi.org\/10.1179\/1607845415Y.0000000009","journal-title":"Hematology"},{"issue":"23","key":"1619_CR23","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d\u2019Amore ES, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, Mullauer L, Carobbio A, Gianatti A, Gangat N, Hanson CA, Tefferi A (2011) Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 29(23):3179\u20133184. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.34.5298","journal-title":"J Clin Oncol"},{"issue":"26","key":"1619_CR24","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A (2012) Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120(26):5128\u20135133. \n                    https:\/\/doi.org\/10.1182\/blood-2012-07-444067\n                    \n                   (quiz 5252)","journal-title":"Blood"},{"key":"1619_CR25","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1038\/bcj.2015.94","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Finazzi G, Carobbio A, Thiele J, Passamonti F, Falcone C, Tefferi A (2015) Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J 5:e369. \n                    https:\/\/doi.org\/10.1038\/bcj.2015.94","journal-title":"Blood Cancer J"},{"issue":"20","key":"1619_CR26","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1182\/blood-2016-05-643346","volume":"128","author":"E Rumi","year":"2016","unstructured":"Rumi E, Cazzola M (2016) How I treat essential thrombocythemia. Blood 128(20):2403\u20132414. \n                    https:\/\/doi.org\/10.1182\/blood-2016-05-643346","journal-title":"Blood"},{"issue":"10","key":"1619_CR27","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1182\/blood-2012-10-429134","volume":"121","author":"C Patrono","year":"2013","unstructured":"Patrono C, Rocca B, De Stefano V (2013) Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood 121(10):1701\u20131711. \n                    https:\/\/doi.org\/10.1182\/blood-2012-10-429134","journal-title":"Blood"},{"issue":"1","key":"1619_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/jca.20266","volume":"26","author":"D Duvall","year":"2011","unstructured":"Duvall D (2011) Therapeutic cytapheresis: too many platelets, too many white blood cells. J Clin Apher 26(1):47\u201352. \n                    https:\/\/doi.org\/10.1002\/jca.20266","journal-title":"J Clin Apher"},{"issue":"21","key":"1619_CR29","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1182\/blood-2015-01-624536","volume":"125","author":"L Pieri","year":"2015","unstructured":"Pieri L, Pancrazzi A, Pacilli A, Rabuzzi C, Rotunno G, Fanelli T, Guglielmelli P, Fjerza R, Paoli C, Verstovsek S, Vannucchi AM (2015) JAK2V617F complete molecular remission in polycythemia vera\/essential thrombocythemia patients treated with ruxolitinib. Blood 125(21):3352\u20133353. \n                    https:\/\/doi.org\/10.1182\/blood-2015-01-624536","journal-title":"Blood"},{"issue":"1","key":"1619_CR30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1309\/AJCPALP51XDIXDDV","volume":"144","author":"Y Lin","year":"2015","unstructured":"Lin Y, Liu E, Sun Q, Ma J, Li Q, Cao Z, Wang J, Jia Y, Zhang H, Song Z, Ai X, Shi L, Feng X, Li C, Wang J, Ru K (2015) The prevalence of JAK2, MPL, and CALR mutations in chinese patients with BCR-ABL1-negative myeloproliferative neoplasms. Am J Clin Pathol 144(1):165\u2013171. \n                    https:\/\/doi.org\/10.1309\/AJCPALP51XDIXDDV","journal-title":"Am J Clin Pathol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-018-1619-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-018-1619-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-018-1619-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T20:38:16Z","timestamp":1549399096000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-018-1619-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["1619"],"URL":"https:\/\/doi.org\/10.1007\/s11239-018-1619-0","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,6]]},"assertion":[{"value":"6 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"In keeping with the Duke IRB policy, the review of medical records for publication of a single case report is not considered to be research involving human subjects, and therefore such a report does not require IRB review and approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}